参考文献/References:
[1]中国高血压防治指南修订委员会,中国高血压联盟,中华医学会心血管病学分会,中国医师协会高血压专业委员会,等.中国高血压防治指南( 2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.
[2]温改艳,袁洪,舒婧娴,等.抗高血压药物的研究现状[J].中国临床药理学杂志,2017,33(24):2629-2632.
[3] Okamura K,Takamiya Y,MoriK,et al.Add-on aliskiren treatment can decrease blood pressure but requires attention to risks of renal impairment and hyperkalemia Chikushi Anti-Hypertension Trial-Rasilez(R) (CHAT-Ras)[J].ClinExp Hypertens,2020,42(6):545-552.
[4] Omboni S,Malacco E,Napoli C,et al.Efficacy of Zofenoprilvs.Irbesartan in combination with a thiazide diuretic in hypertensive patients with multiple risk factors not controlled by a previous monotherapy: a review of the double-blind,randomized "Z" studies[J].Adv Ther,2017,34(4):784-798.
[5]孟婷婷,赵福军,夏文胜,等.依普利酮与依那普利、氯沙坦降压效果比较的荟萃分析[J].北京医学,2015,37(10):970-973.
[6]Liu LC,Schutte E,Gansevoort RT,et al.Finerenone:third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease[J].Expert OpinInvestig Drugs,2015,24(8):1123-1135.
[7]Dhaun N,Webb DJ.Endothelins in cardiovascular biology and therapeutics[J].Nat Rev Cardiol,2019,16(8):491-502.
[8]Burnier M.Update on endothelin receptor antagonists in hypertension[J].CurrHypertens Rep,2018,20(6):51.
[9]Bakris GL,Lindholm LH,Black HR,et al.Divergent results using clinic and ambulatory blood pressures:report of a darusentan-resistant hypertension trial[J].Hypertension,2010,56(5):824-830.
[10]Yuan W,Cheng G,Li B,et al.Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis[J].Blood Press,2017,26(3):139-149.
[11]Heerspink H,Parving HH,Andress DL,et al.Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind,randomised,placebo-controlled trial[J].Lancet,2019,393(10184):1937-1947.
[12]Kario K.TheSacubitril/Valsartan,a first-in-class,angiotensin receptor neprilysin inhibitor (ARNI): potential uses in hypertension,heartfailure,and beyond[J].CurrCardiol Rep,2018,20(1):5.
[13]Wehland M,Simonsen U,Buus NH,et al.An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension[J].Expert Opin Pharmacother,2020:1-11.
[14]ZhaoY,Yu H,Zhao X,et al.The effects of LCZ696 in patients with hypertension compared with angiotensin receptor blockers: a meta-analysis of randomized controlled trials[J].J CardiovascPharmacol Ther,2017,22(5):447-457.
[15]Marquez DF,Ruiz-Hurtado G,Ruilope LM,etal.An update of the blockade of the renin angiotensin aldosterone system in clinical practice[J].Expert OpinPharmacother,2015,16(15):2283-2292.
[16]Parvanova A,van der Meer IM,Iliev I,et al.Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria:arandomised,crossover,double-blind,placebo-controlled trial[J].Lancet Diabetes Endocrinol,2013,1(1):19-27.
[17]Spencer AG,Labonte ED,Rosenbaum DP,et al.Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans[J] .SciTransl Med,2014,6(227):227r-236r.
[18]Verma S,McMurray JJV.SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review[J].Diabetologia,2018,61(10):2108-2117.
[19]Zelniker TA,Braunwald E.Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes:JACC state-of-the-art review[J].J Am Coll Cardiol,2018,72(15):1845-1855.
[20]Zelniker TA,Wiviott SD,RazI,et al.SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J].Lancet,2019,393(10166):31-39.
[21]蒋昭隆,刘剑雄.SGLT2抑制剂在2型糖尿病患者心血管获益机制[J].海南医学,2019,30(19):2557-2560.
[22]GeorgianosPI,Agarwal R.Ambulatory blood pressure reduction with SGLT-2 inhibitors:dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide[J].Diabetes Care,2019,42(4):693-700.
[23]林春瑜,郑志兵,贾娴,等.可溶性鸟苷酸环化酶刺激剂的研究进展[J].国际药学研究杂志,2018,45(8):575-581.
[24]Sauzeau V,LeJeune H,Cario-Toumaniantz C,et al.Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca2+ sensitization of contraction in vascular smooth muscle[J].J Biol Chem ,2000,275(28):21722-21729.
[25]Ghofrani HA,Humbert M,Langleben D,etal.Riociguat:mode of action and clinical development in pulmonary hypertension[J].Chest,2017,151(2):468-480.
[26]Geschka S,Kretschmer A,Sharkovska Y,et al.Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats[J].Plos One,2011,6(7):e21853.
[27]Marc Y,Hmazzou R,Balavoine F,et al.Central antihypertensive effects of chronic treatment with RB150:an orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats[J].J Hypertens,2018,36(3):641-650.
[28]Ferdinand KC,Balavoine F,Besse B,et al.Efficacy and safety of firibastat,a first-in-class brain aminopeptidase ainhibitor,in hypertensive overweight patients of multiple ethnic origins[J].Circulation,2019,140(2):138-146.
[29]Jordan R,Stark J,Huskey S,et al.PhaseⅠstudy of the novel a-type natriuretic receptor agonist,PL-3994,in healthy volunteers[J].J Cardiac Fail,2008,14(suppl1):S70-S70.
[30]Couvineau A,Laburthe M.VPAC receptors:structure,molecular pharmacology and interaction with accessory proteins[J].Br J Pharmacol,2012,166(1):42-50.
[31]Oparil S,Schmieder RE.New approaches in the treatment of hypertension[J].Circ Res,2015,116(6):1074-1095.
[32]Igreja B,Wright LC,Soares-Da-Silva P.Sustained high blood pressure reduction with etamicastat,a peripheral selective dopamine beta-hydroxylase inhibitor[J].J Am Soc Hypertens,2016,10(3):207-216.
[33]Igreja B,Pires NM,Bonifacio MJ,et al.Blood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive rat[J].Hypertens Res,2015,38(1):30-38.
相似文献/References:
[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(10):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(10):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(10):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(10):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(10):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(10):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(10):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(10):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]